Ashish Kamat, Endowed Professor and Surgeon at MD Anderson Cancer Center, shared on X:
“On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech) for adults with BCG – unresponsive NMIBC with CIS with or without papillary tumors.
Also known as TAR-200: this gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.”
More posts featuring Ashish M. Kamat.